Imagine a future where cancer patients are able to receive the treatment they precisely need and not the treatment that is prescribed to all.
In January, after tumultuous weeks filled with unprecedented political tension and rising COVID-19 infections across the nation, thrilling news arrived quietly in my email inbox: official notice of the Abramson Cancer Center's five-year, $45 million Cancer Center Support Grant award from the National Cancer Institute, which had bestowed us with a merit rating of “Exceptional” Comprehensive Cancer Center last year.
Cancer patients and survivors should not get COVID-19. A three-time cancer survivor should definitely not get COVID. But I did. And it was not good. Here is my story and the lessons I learned that might be of value to others.
President Donald Trump is hardly the first septuagenarian world leader to mistrust doctors and science.
The recent historic election of President-elect Joe Biden and Vice President-elect Kamala Harris provides an exciting opportunity for the cancer research and medical science communities during the next four years to dramatically improve the health of our nation and the world.
Over the past five decades, a marked shift in the number of women practicing gynecologic oncology has transformed the field. The specialty began as 57 men gynecologists, who saw an unmet need in the care of women with malignancies of the female genital tract.
The global coronavirus pandemic has torn the veil that dimmed the nation's awareness of the breadth and depth of health disparities, including cancer health disparities.
Last week, a national public perception survey from the American Society of Clinical Oncology revealed a public grappling with cancer care amid the COVID-19 pandemic and the nation's reckoning with racial injustice.
Diversity, inclusion, and equity are important issues, not only to our nation's cancer centers, but to our nation as a whole. To embody these values, we must work to close gaps in cancer research and care.
As of September, more than 270,000 deaths have been confirmed in Latin American countries due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
